LAB Q4 2022 Earnings — Standard BioTools Inc. Revenue & Financial Results | Market Cap Arena

LABStandard BioTools Inc.

$388M

Q4 2022 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$27M-29.4% YoY

Gross Profit

$11M41.3% margin

Operating Income

-$21M-78.1% margin

Net Income

-$21M-77.1% margin

EPS (Diluted)

$-0.26

QoQ Revenue Growth

+5.4%

Cash Flow

Operating Cash Flow

-$19M

Free Cash Flow

-$20M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$390M

Total Liabilities

$472M

Stockholders' Equity

-$81M

Cash & Equivalents

$81M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$27M	$38M	-29.4%
Gross Profit	$11M	$20M	-44.8%
Operating Income	-$21M	-$11M	-87.5%
Net Income	-$21M	-$9M	-121.1%

Revenue Segments

Product And Service

$27M51%

Product

$21M39%

Service

$6M11%

Product and Service, Other

-$621,000-1%

Geographic Segments

EMEA

$11M40%

Americas

$11M39%

Asia Pacific

$6M21%